Navigating Avadel’s Potential And Risks With Lumryz (NASDAQ:AVDL)

asian man in bed suffering insomnia and sleep disorder thinking about his problem at night

yanyong/iStock via Getty Images


Avadel Pharmaceuticals (NASDAQ:AVDL) is a pharmaceutical company with a lead product candidate called Lumryz, also known as FT218. Lumryz is an investigational extended-release formulation of sodium oxybate used to treat excessive daytime sleepiness [EDS] and

Sleepiness Severity First-Line Medications Alternatives
Mild to Moderate Modafinil, Armodafinil, Pitolisant, Solriamfetol
Severe/Disabling Oxybates Solriamfetol, Methylphenidate, Amphetamines, Medication Combinations
Residual Cataplexy Serotonergic Antidepressant (Venlafaxine), Pitolisant Oxybates

Leave a Reply

Your email address will not be published. Required fields are marked *